Market Update: Merck & Co Inc (NYSE:MRK) – Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

[Business Wire] – Merck , known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology . . . → Read More: Market Update: Merck & Co Inc (NYSE:MRK) – Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers Similar Articles: Market Update: Merck & Co Inc (NYSE:MRK) – Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Final Results of Tender Offers for Eight Series of Notes Company Update: Merck & Co Inc (NYSE:MRK) – Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion